The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 18, 2025
Filed:
Jun. 28, 2019
Applicant:
Taiho Pharmaceutical Co., Ltd., Tokyo, JP;
Inventor:
Yuki Tanaka, Ibaraki, JP;
Assignee:
Taiho Pharmaceutical Co., Ltd., Tokyo, JP;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/65 (2017.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
A61K 47/65 (2017.08); A61K 39/0011 (2013.01); A61K 39/001102 (2018.08); A61K 39/00119 (2018.08); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/545 (2013.01); A61K 2039/627 (2013.01); A61K 2039/70 (2013.01);
Abstract
Provided is a novel cancer treatment method that exhibits a significantly excellent antitumor effect and causes less adverse reactions. The present invention provides an antitumor agent wherein a peptide having 4 linked epitopes and an immune checkpoint modulator are administered in combination. An antitumor effect in humans can be evaluated by providing a cell coexpressing an epitope peptide of a human tumor antigen derived from SART2 and human HLA-A24.